BioLargo Inks Aquatech MOU to Accelerate PFAS Treatment Commercialization
BLGO is trading near its 52-week low of $0.138 (10% above the low) on light trading volume (0.4× avg).
Summary
BioLargo, through its subsidiary, has signed a Memorandum of Understanding (MOU) with Aquatech, a globally recognized leader in water treatment, to accelerate the commercialization of its proprietary Aqueous Electrostatic Concentrator (AEC) technology for PFAS treatment. This partnership is highly significant for the small-cap company, as it provides a pathway to integrate BioLargo's innovative PFAS removal solution into Aquatech's comprehensive treatment offerings and leverage Aquatech's extensive market reach. The collaboration aims to deliver scalable PFAS treatment solutions for industrial, municipal, and government clients worldwide, addressing a critical and rapidly growing environmental remediation market. This positive development follows a recent $1.2 million contract win for BioLargo's engineering subsidiary, signaling continued operational momentum. Investors should watch for specific project announcements or definitive agreements stemming from this non-exclusive framework.
At the time of this announcement, BLGO was trading at $0.15 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $48.9M. The 52-week trading range was $0.14 to $0.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.